TITAN BIOTECH
TITAN BIOTECH LIMITED
AN ISO 9001:2015 CERTIFIED COMPANY
TMMEDIA
Office: 903-909. 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Telephone no.: 011-27355742, 71239900(44 Lines), CIN: L74999RJ1992PLC013387

August 13, 2026

To,
Corporate Services Department,
BSE Ltd.,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai- 400001

BSE Scrip Code: 524717
ISIN: INE150C01029

Dear Sir,

Sub: Outcome of Meeting of the Board of Directors of Titan Biotech Limited (the Company) held on August 13, 2026

In terms of the requirements of Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circulars, as amended from time to time, this is to inform you that the Board of Directors at its meeting held today, i.e. Thursday, August 13, 2026, has, *inter- alia a*pproved the Unaudited Standalone and Consolidated financial results of the Company for the quarter ended June 30, 2026 as reviewed by the Audit Committee and approved by the Board of Directors of the Company.

Please find enclosed, unaudited financial result (Standalone & Consolidated) along with the Limited Review Report issued by the statutory auditors of the Company for the quarter ended June 30, 2026.

The meeting of Board of Directors commenced at **03:00 P.M. and concluded at 03:40 P.M**.

The above information will be available on the website of the company i.e www.titanbiotechltd.com and BSE Ltd i.e www.bseindia.com.

Request to kindly take this information on record and acknowledge.

For and on behalf of
Titan Biotech Limited
CHARANJIT SINGH
Digitally signed by CHARANJIT SINGH
Date: 2026.08.13 15:46:32 +05'30'
Charanjit Singh
Company Secretary & Compliance Officer
M.No A12726

TITAN BIOTECH LIMITED

Encl: As above

A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 705, GDITL Tower, B-08, Netaji Subhash Place,
Pitampura, Delhi-110034
OFFICE NO. 011-46010089
EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly and year to date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,
The Board of Directors
Titan Biotech Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Titan Biotech Limited (the "Company"), for the quarter ended June 30, 2026 and the year to date results for the period April 1, 2026 to June 30, 2026 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Repot Ling" ("Ind AS 34"), prescribed under Section 193 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For A N S K & Associates
Chartered Accountants
Firm's Registration No. 026177N

KAPIL SINGHAL
Digitally signed by KAPIL SINGHAL
Date: 2026.08.13 15:10:25 +05'30'

Kapil Singal
Partner
M.No. 520205
Date: 13 August 2026
Place: New Delhi
UDIN: 26520205ZVNNEM1511

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	STANDALONE			
		QUARTER ENDED			YEAR ENDED
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	**INCOME**				
	Revenue from operations	5,916.66	4,883.35	4,649.64	20,619.03
	Other income	181.26	210.64	72.22	541.02
	Total income	**6,097.92**	**5,093.99**	**4,721.86**	**21,160.05**
2	**EXPENSES**				
	Cost of materials consumed	2,992.80	2,590.68	1,855.28	9,916.35
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(203.91)	(707.75)	539.67	(296.82)
	Employee benefits expense	869.68	943.53	701.32	3,236.20
	Finance costs	19.88	23.72	19.52	91.39
	Depreciation and amortization expense	136.69	129.75	115.20	492.53
	Other expenses	1,009.36	1,085.89	679.66	3,902.95
	Total expenses	**4,824.50**	**4,065.82**	**3,910.65**	**17,342.60**
3	**Profit before exceptional items and tax (1-2)**	1,273.42	1,028.17	811.21	3,817.45
4	Exceptional items		-	-	-
5	**Profit before tax (3+4)**	1,273.42	1,028.17	811.21	3,817.45
6	Tax expense:				
	(I) Current tax	321.79	302.22	192.28	988.74
	(II) Deferred tax	6.04	70.38	2.85	83.99
	(III) Earlier year taxes		-	-	-
	Total tax (I+II+III)	327.83	372.60	195.13	1,072.73
7	**Profit for the period (5-6)**	**945.59**	**655.57**	**616.08**	**2,744.72**
8	**Other comprehensive income**				
A.	(i) Items that will not be reclasssified to profit or loss				
	(ia) Re-measurement gain on defined benefit plans	(3.05)	(19.51)	2.44	(12.19)
	(ii) Income tax on the above item	0.77	5.38	(0.61)	3.54
B.	(i) Items that will be reclasssified to profit or loss		-	-	-
	(ii) Income tax on the above item		-	-	-
	Total other comprehensive income for the period (A+B) (net of taxes)	**(2.28)**	**(14.13)**	**1.83**	**(8.65)**
9	**Total comprehensive income for the period (7+8)**	**943.31**	**641.44**	**617.91**	**2,736.07**
10	Paid-up equity share capital (face value of Rs. 2/- each)	826.37	826.37	826.37	826.37
11	Other Equity				16,257.78
12	Earnings per equity share (face value of Rs.2/- each) not annualised				
	(1) Basic	2.29	1.59	7.46	6.64
	(2) Diluted	2.29	1.59	7.46	6.64

Notes:

1. The above standalone unaudited financial results for the quarter ended on 30.06.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 13, 2026.The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirments), 2015.The results for the quarter ended June 30, 2026, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)
2. Previous period figures are regrouped/reclassified in line with the current period.
3. The Company has only one reportable busines segment.
4. The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
5. Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 13.08.2026

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2026

(Rs. IN LAKHS) except for EPS

Sr. No.	PARTICULARS	STANDALONE			
		QUARTER ENDED			YEAR ENDED
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total income from operations (Net)	6,097.92	5,093.99	4,721.86	21,160.05
2	Net Profit for the period (before tax,exceptional and/or extraordinary items)	1,273.42	1,028.17	811.21	3,817.45
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	1,273.42	1,028.17	811.21	3,817.45
4	Net Profit for the period after tax (after exceptional and/or extraordinary items)	945.59	655.57	616.08	2,744.72
5	Total comprehensive income for the period (comprising Profit for the period (after tax) and other comprehensive income(after tax)(refer note 3)	943.31	641.44	617.91	2,736.07
6	Paid-up equity share capital (Face value of Rs. 2/- per share)	826.37	826.37	826.37	826.37
7	Other equity excluding revaluation reserves as per the balance sheet	-	-	-	16,257.78
8	Earnings per share (of INR 2/- each)				
	(a) Basic	2.29	1.59	7.46	6.64
	(b) Diluted	2.29	1.59	7.46	6.64

NOTES :

1 The above is an extract of the detailed format of standalone unaudited Financial Results for the quarter ended on 30.06.2026 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone unaudited Financial Results for the said quarter ended on 30.06.2026 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com.

2 The above standalone unaudited financial results for the quarter ended on 30.06.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at its meeting held on August 13, 2026.The Statutory Auditors of the Company have carried out a limited review in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirments), 2015.The results for the quarter ended June 30, 2026, are available on the BSE Limited website(www.bseindia.com) and on the company's Website(www.titanbiotechltd.com)

3 The standalone unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").

4 Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 13.08.2026

A N S K & Associates
CHARTERED ACCOUNTANTS
OFFICE : 705, GDITL Tower, B-08, Netaji Subhash Place, Pitampura, Delhi-110034
OFFICE NO. 011-46010089
EMAIL :amccorporateservices@gmail.com

Independent Auditor's Review Report on Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To,

THE BOARD OF DIRECTORS
TITAN BIOTECH LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of Titan Biotech Limited (the "Company") and its Associates, for the quarter ended June 30, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

A N S K & Associates

CHARTERED ACCOUNTANTS

OFFICE : 705, GDITL Tower, B-08, Netaji Subhash Place,

Pitampura, Delhi-110034

OFFICE NO. 011-46010089

EMAIL :amccorporateservices@gmail.com

4. The Statement includes results of the Holding Company -Titan Biotech Limited and its Associate Company - Peptech Biosciences Limited and Titan Media Limited.
5. The accompanying unaudited consolidated financial results includes unaudited interim financial results and other unaudited financial information in respect of its associates which have been approved and furnished to us by the management. Our Conclusion on the statement is not modified in respect of the above matter.

6. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 and Regulation 52 read with Regulation 63(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The unaudited consolidated financial results also includes the Group's share of net profit after tax of Rs. 140.09 lacs and other comprehensive income of Rs. (0.04) Lacs for the Quarter ended June 30, 2026 as considered in the consolidated unaudited financial results, in respect of its Associates, based on their interim financial results of M/s Peptech biosciences Limited and M/s Titan Media Limited which have been reviewed by our Audit Firm. Our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of its associates, are based solely on such unaudited interim financial results. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

   Our conclusion is not modified in respect of this matter.

For A N S K & Associates
Chartered Accountants
Firm's Registration No. 026177N

KAPIL SINGHAL
Digitally signed by KAPIL SINGHAL
Date: 2026.08.13 15:11:30 +05'30'

Kapil Singal
Partner
M.No. 520205
Date: 13.08.2026
Place: New Delhi
UDIN: 26520205REAMKZ3140

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A, RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011-71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED			YEAR ENDED
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	**INCOME**				
	Revenue from operations	5,916.66	4,883.35	4,649.64	20,619.03
	Other income	181.26	210.64	72.22	541.02
	Total income	**6,097.92**	**5,093.99**	**4,721.86**	**21,160.05**
2	**EXPENSES**				
	Cost of materials consumed	2,992.80	2,590.68	1,855.28	9,916.35
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(203.91)	(707.75)	539.67	(296.82)
	Employee benefits expense	869.68	943.53	701.32	3,236.20
	Finance costs	19.88	23.72	19.52	91.39
	Depreciation and amortization expense	136.69	129.75	115.20	492.53
	Other expenses	1,009.36	1,085.89	679.66	3,902.95
	Total expenses	**4,824.50**	**4,065.82**	**3,910.65**	**17,342.60**
3	**Profit before exceptional items and tax (1-2)**	**1,273.42**	**1,028.17**	**811.21**	**3,817.45**
4	Exceptional items	-	-	-	-
5	Profit before tax (3+4)	1,273.42	1,028.17	811.21	3,817.45
6	Tax expense				
	(I) Current tax	321.79	302.22	192.28	988.74
	(II) Deferred tax	6.04	70.38	2.85	83.99
	(III) Earlier year taxes	-	-	-	-
	Total tax (I+II+III)	327.83	372.60	195.13	1,072.73
7	Profit for the period (5-6)	**945.59**	**655.57**	**616.08**	**2,744.72**
8	Share in profit of associate	**140.09**	**17.34**	**70.20**	**243.80**
9	Profit for the period (7+8)	**1,085.68**	**672.91**	**686.28**	**2,988.52**
10	**Other comprehensive income**				
A.	(i) Items that will not be reclasssified to profit or loss				
	(ia) Re-measurement gain on defined benefit plans	(3.05)	(19.51)	2.44	(12.19)
	(ii) Income tax on the above item	0.77	5.38	(0.61)	3.54
B	(i) Items that will be reclasssified to profit or loss		-	-	-
	(ii) Income tax on the above item		-	-	-
	Share in other comprehensive income of associate	(0.04)	(0.17)		(0.17)
	Total other comprehensive income for the period (A+B) (net of taxes)	**(2.32)**	**(14.30)**	**1.83**	**(8.82)**
11	**Total comprehensive income for the period (7+8)**	**1,083.36**	**658.61**	**688.11**	**2,979.70**
12	**Net profit attributable to:**				
	Owners of the holding company				
	Non-controlling interest				
13	**Other comprehensive income attributable to :**				
	Owners of the holding company				
	Non-controlling interest				
14	**Total comprehensive income attributable to (10+11)**				
	Owners of the holding company				
	Non-controlling interest				
15	Paid-up equity share capital (face value of Rs 2/- each)	826.37	826.37	826.37	826.37
16	Other Equity				17,328.38
17	Earnings per equity share (face value of Rs 2/- each) not annualised				
	(1) Basic	2.63	1.63	8.30	7.23
	(2) Diluted	2.63	1.63	8.30	7.23

Notes:

1. The above consolidated unaudited financial results for the quarter ended on 30.06.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 13, 2026. The statutory auditors of the Company have carried out a limited review of the aforesaid results. The results for the quarter ended June 30, 2026, are available on the BSE Limited website(www.bseindia.com) and on the Company's Website(www.titanbiotechltd.com)
2. The consolidated unaudited financial results for the quarter ended on 30.06.2026 include the results of following -
   Associate Companies - Peptech Biosciences Limited and Titan Media Limited
3. Previous period figures are regrouped/reclassified in line with the current period.
4. The Company has only one reportable business segment.
5. The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India").
6. Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

TITAN BIOTECH LIMITED

Place : Delhi
Dated : 13.08.2026

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RIICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019

Phone No. 011- 71239900, Email : hrd@titanbiotechltd.com, www.titanbiotechltd.com, CIN : L74999RJ1992PLC013387

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2026

(Rs. IN LAKHS) except for EPS

Sr. No	PARTICULARS	CONSOLIDATED			
		QUARTER ENDED			YEAR ENDED
		30.06.2026	31.03.2026	30.06.2025	31.03.2026
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
1	Total income from operations (Net)	6,097.92	5,093.99	4,721.86	21,160.05
2	Net Profit for the period (before tax,exceptional and/or extraordinary items)	1,273.42	1,028.17	811.21	3,817.45
3	Net profit for the period before tax (after exceptional and/or extraordinary items)	1,273.42	1,028.17	811.21	3,817.45
4	Net profit for the period after tax (after exceptional and/or extraordinary items)	1,085.68	672.91	686.28	2,988.52
5	Total comprehensive income for the period (comprising Profit for the period(after tax) and other comprehensive income(after tax)(refer note 3)	1,083.36	658.61	688.11	2,979.70
6	Paid-up equity share capital (face value of Rs. 2/- per share)	826.37	826.37	826.37	826.37
7	Other equity excluding revaluation reserves as per the balance sheet	-	-	-	17,328.38
8	Earnings per share (of INR 2/- each)				
	(a) Basic	2.63	1.63	8.30	7.23
	(b) Diluted	2.63	1.63	8.30	7.23

NOTES :

1. The above is an extract of the detailed format of consolidated unaudited Financial Results for the quarter ended on 30.06.2026 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated unaudited Financial Results for the said quarter ended on 30th June 2026 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechltd.com
2. The above consolidated unaudited financial results for the quarter ended on 30.06.2026 have been reviewed by the Audit Committee and taken on record by the Board of Directors of the Company at their respective meeting held on August 13, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
3. The consolidated unaudited financial results have been prepared in accordance with the Indian Accounting Standards ('Ind AS') specified in the Companies (Indian Accounting Standards) Rules 2015 (as amended) under section 133 of the Companies Act 2013 (the "accounting principles generally accepted in India")
4. Freight amount has been added in revenue from operations for the purpose of calculation of sales including GST in current year. Freight also added in total in other expenses to neutralise the impact of its addition in revenue in current year.

For and on behalf of Board of Directors
for TITAN BIOTECH LIMITED

TITAN BIOTECH LIMITED

NARESH KUMAR SINGLA
Managing Director
DIN-00027448

Place : Delhi
Dated : 13.08.2026